Predictive Vulnerability Intelligence.

Product

  • Product
  • Pricing
  • Documentation

Company

  • About
  • Partnerships
  • Blog
  • Support

Legal

  • Terms
  • Privacy
  • Data Licensing

© 2026 FAUCET Technologies LLC. All rights reserved.

CVE-2019-15934

25
FAUCET Score

CVE-2019-15934 describes a Cross-Site Request Forgery (CSRF) vulnerability in Intesync Solismed 3.3sp. This high-severity vulnerability, rated 8.8 CVSS, allows an unauthenticated attacker to execute arbitrary actions with high impact on confidentiality, integrity, and availability, requiring user interaction. Despite its severity, there is no evidence of active exploitation, publicly available exploit code, or significant community discussion surrounding this CVE.

Impacted Technologies

VendorProductVersion(s)CPE
3.3CPE matchmatch criteria
cpe:2.3:a:intesync:solismed:3.3:sp1:*:*:*:*:*:*

CVSS Data

CVSS version used by this source: 3.1

8.8HIGH

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Attack Vector
NETWORK
Attack Complexity
LOW
Privileges Required
NONE
User Interaction
REQUIRED
Scope
UNCHANGED
Confidentiality Impact
HIGH
Integrity Impact
HIGH
Availability Impact
HIGH
Exploitability Score
2.8
Impact Score
5.9
CvssVersion
3.1

Exploit Intelligence

EPSS Score
0.86%
Probability of exploitation in next 30 days
EPSS Percentile
54.6%
Percentile rank of EPSS score among Peer Group
As of 2026-07-24
Model: v2026.06.15
This CVE's current EPSS score of 0.0086 is in the 56th percentile among its peer group of 14,824 CVEs.

Social Chatter

The average CVE in this peer group has 0.0 Twitter, 0.1 Reddit, 0.2 Bluesky, 0.1 Mastodon, and 0.2 GitHub mentions.

Media Mentions

No media coverage found for this CVE.

The average CVE in this peer group has 0.3 InfoSec Media, 0.0 Vendor Blog, and 0.1 Security Researcher mentions.

Remediation

Remediation records are not available for this CVE.

References

bishopfox.com
Third Party Advisory
know.bishopfox.com / advisories/solismed-critical
ExploitThird Party Advisory
bishopfox.com / blog/news-category/advisories
Third Party Advisory
solismed.com
Product